ID

31766

Description

Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074); ODM derived from: https://clinicaltrials.gov/show/NCT00642954

Link

https://clinicaltrials.gov/show/NCT00642954

Keywords

Versions (1)
  1. 9/26/18 9/26/18 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

September 26, 2018

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Relapsed or Refractory Multiple Myeloma NCT00642954

English

Eligibility Relapsed or Refractory Multiple Myeloma NCT00642954

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
patient is a male or female at least 18 years old
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
patient has relapsed or refractory mm and has had at least one prior therapy
Description

Relapse multiple myeloma | Refractory multiple myeloma | Prior Therapy Quantity

Data type

boolean

Alias
UMLS CUI [1]
C2349261
UMLS CUI [2]
C0278620
UMLS CUI [3,1]
C1514463
UMLS CUI [3,2]
C1265611
female patients of childbearing potential must have 2 negative serum pregnancy tests prior to receiving the first dose of study drugs
Description

Childbearing Potential Serum pregnancy test negative Quantity

Data type

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0430061
UMLS CUI [1,3]
C1265611
female patients who can become pregnant must agree to use 2 separate forms of effective birth control at the same time, 4 weeks before, while taking, and for 4 weeks after stopping lenalidomide. post menopausal patients should be free from menses for > 2 years, or are surgically sterilized
Description

Childbearing Potential Contraceptive methods Quantity | Lenalidomide Discontinued | Postmenopausal state | Female Sterilization

Data type

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0700589
UMLS CUI [1,3]
C1265611
UMLS CUI [2,1]
C1144149
UMLS CUI [2,2]
C1444662
UMLS CUI [3]
C0232970
UMLS CUI [4]
C0015787
male patient agrees to use an adequate method of contraception for the duration of the study, even if the patient has undergone a successful vasectomy
Description

Gender Contraceptive methods | Vasectomy Successful

Data type

boolean

Alias
UMLS CUI [1,1]
C0079399
UMLS CUI [1,2]
C0700589
UMLS CUI [2,1]
C0042387
UMLS CUI [2,2]
C1272703
male patients must agree to use a latex condom during sexual contact with a pregnant female or a female who can become pregnant. this is required for the duration of the study, and for 4 weeks after stopping therapy
Description

Gender Use of Latex condom

Data type

boolean

Alias
UMLS CUI [1,1]
C0079399
UMLS CUI [1,2]
C1524063
UMLS CUI [1,3]
C3873750
patient has at least 3 weeks washout prior to treatment
Description

Washout Period Duration

Data type

boolean

Alias
UMLS CUI [1,1]
C1710661
UMLS CUI [1,2]
C0449238
patient is able to swallow capsules and is able to take or tolerate oral medications on a continuous basis
Description

Able to swallow capsules | Ability Intake Oral medication | Ability Receive Oral medication

Data type

boolean

Alias
UMLS CUI [1,1]
C2712086
UMLS CUI [1,2]
C0006935
UMLS CUI [2,1]
C0085732
UMLS CUI [2,2]
C1512806
UMLS CUI [2,3]
C0175795
UMLS CUI [3,1]
C0085732
UMLS CUI [3,2]
C1514756
UMLS CUI [3,3]
C0175795
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
patient has prior treatment with an histone deacetylase (hdac) inhibitor
Description

Histone deacetylase inhibitor

Data type

boolean

Alias
UMLS CUI [1]
C1512474
patient has prior allogenetic bone marrow transplant
Description

Allogeneic bone marrow transplantation

Data type

boolean

Alias
UMLS CUI [1]
C0149615
patient has received intravenous antibiotics, antiviral, or antifungal agents within 2 weeks prior to the start of the study drug
Description

Antibiotics Intravenous | Antiviral Agents Intravenous | Antifungal Agents Intravenous

Data type

boolean

Alias
UMLS CUI [1,1]
C0003232
UMLS CUI [1,2]
C1522726
UMLS CUI [2,1]
C0003451
UMLS CUI [2,2]
C1522726
UMLS CUI [3,1]
C0003308
UMLS CUI [3,2]
C1522726
patient uses illicit drugs, substance abuse or had a recent history (within the last year) of drug or alcohol abuse
Description

Illicit medication use | Substance Use Disorders

Data type

boolean

Alias
UMLS CUI [1]
C0281875
UMLS CUI [2]
C0038586
patient is pregnant or breast feeding or expecting to have a baby during the course of the study
Description

Pregnancy | Breast Feeding | Pregnancy Expected

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3,1]
C0032961
UMLS CUI [3,2]
C1517001
patient has human immunodeficiency virus (hiv) infection
Description

HIV Infection

Data type

boolean

Alias
UMLS CUI [1]
C0019693
patient has hepatitis b/c infection
Description

Hepatitis B | Hepatitis C

Data type

boolean

Alias
UMLS CUI [1]
C0019163
UMLS CUI [2]
C0019196
patient is currently receiving treatment for another type of cancer other than skin or cervical cancer that has not been in remission for 5 years or longer
Description

Therapeutic procedure Cancer Other | Exception Skin carcinoma | Exception Cervix carcinoma | Cancer Remission Absent

Data type

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C1707251
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0699893
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0302592
UMLS CUI [4,1]
C0687702
UMLS CUI [4,2]
C0332197
Back to the top of the page

Similar models

Eligibility Relapsed or Refractory Multiple Myeloma NCT00642954

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
patient is a male or female at least 18 years old
boolean
C0001779 (UMLS CUI [1])
Relapse multiple myeloma | Refractory multiple myeloma | Prior Therapy Quantity
Item
patient has relapsed or refractory mm and has had at least one prior therapy
boolean
C2349261 (UMLS CUI [1])
C0278620 (UMLS CUI [2])
C1514463 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
Childbearing Potential Serum pregnancy test negative Quantity
Item
female patients of childbearing potential must have 2 negative serum pregnancy tests prior to receiving the first dose of study drugs
boolean
C3831118 (UMLS CUI [1,1])
C0430061 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
Childbearing Potential Contraceptive methods Quantity | Lenalidomide Discontinued | Postmenopausal state | Female Sterilization
Item
female patients who can become pregnant must agree to use 2 separate forms of effective birth control at the same time, 4 weeks before, while taking, and for 4 weeks after stopping lenalidomide. post menopausal patients should be free from menses for > 2 years, or are surgically sterilized
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C1144149 (UMLS CUI [2,1])
C1444662 (UMLS CUI [2,2])
C0232970 (UMLS CUI [3])
C0015787 (UMLS CUI [4])
Gender Contraceptive methods | Vasectomy Successful
Item
male patient agrees to use an adequate method of contraception for the duration of the study, even if the patient has undergone a successful vasectomy
boolean
C0079399 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0042387 (UMLS CUI [2,1])
C1272703 (UMLS CUI [2,2])
Gender Use of Latex condom
Item
male patients must agree to use a latex condom during sexual contact with a pregnant female or a female who can become pregnant. this is required for the duration of the study, and for 4 weeks after stopping therapy
boolean
C0079399 (UMLS CUI [1,1])
C1524063 (UMLS CUI [1,2])
C3873750 (UMLS CUI [1,3])
Washout Period Duration
Item
patient has at least 3 weeks washout prior to treatment
boolean
C1710661 (UMLS CUI [1,1])
C0449238 (UMLS CUI [1,2])
Able to swallow capsules | Ability Intake Oral medication | Ability Receive Oral medication
Item
patient is able to swallow capsules and is able to take or tolerate oral medications on a continuous basis
boolean
C2712086 (UMLS CUI [1,1])
C0006935 (UMLS CUI [1,2])
C0085732 (UMLS CUI [2,1])
C1512806 (UMLS CUI [2,2])
C0175795 (UMLS CUI [2,3])
C0085732 (UMLS CUI [3,1])
C1514756 (UMLS CUI [3,2])
C0175795 (UMLS CUI [3,3])
Item Group
C0680251 (UMLS CUI)
Histone deacetylase inhibitor
Item
patient has prior treatment with an histone deacetylase (hdac) inhibitor
boolean
C1512474 (UMLS CUI [1])
Allogeneic bone marrow transplantation
Item
patient has prior allogenetic bone marrow transplant
boolean
C0149615 (UMLS CUI [1])
Antibiotics Intravenous | Antiviral Agents Intravenous | Antifungal Agents Intravenous
Item
patient has received intravenous antibiotics, antiviral, or antifungal agents within 2 weeks prior to the start of the study drug
boolean
C0003232 (UMLS CUI [1,1])
C1522726 (UMLS CUI [1,2])
C0003451 (UMLS CUI [2,1])
C1522726 (UMLS CUI [2,2])
C0003308 (UMLS CUI [3,1])
C1522726 (UMLS CUI [3,2])
Illicit medication use | Substance Use Disorders
Item
patient uses illicit drugs, substance abuse or had a recent history (within the last year) of drug or alcohol abuse
boolean
C0281875 (UMLS CUI [1])
C0038586 (UMLS CUI [2])
Pregnancy | Breast Feeding | Pregnancy Expected
Item
patient is pregnant or breast feeding or expecting to have a baby during the course of the study
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0032961 (UMLS CUI [3,1])
C1517001 (UMLS CUI [3,2])
HIV Infection
Item
patient has human immunodeficiency virus (hiv) infection
boolean
C0019693 (UMLS CUI [1])
Hepatitis B | Hepatitis C
Item
patient has hepatitis b/c infection
boolean
C0019163 (UMLS CUI [1])
C0019196 (UMLS CUI [2])
Therapeutic procedure Cancer Other | Exception Skin carcinoma | Exception Cervix carcinoma | Cancer Remission Absent
Item
patient is currently receiving treatment for another type of cancer other than skin or cervical cancer that has not been in remission for 5 years or longer
boolean
C0087111 (UMLS CUI [1,1])
C1707251 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0699893 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0302592 (UMLS CUI [3,2])
C0687702 (UMLS CUI [4,1])
C0332197 (UMLS CUI [4,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial